St. Jude Medical Inc. (NYSE:STJ) hit a new 52-week high on Monday . The stock traded as high as $84.00 and last traded at $83.58, with a volume of 498,101 shares changing hands. The stock had previously closed at $83.90.

Several equities research analysts recently weighed in on STJ shares. Zacks Investment Research cut St. Jude Medical from a “hold” rating to a “sell” rating in a report on Tuesday, April 12th. Bank of America Corp. reaffirmed a “buy” rating and set a $66.00 price target on shares of St. Jude Medical in a research report on Friday, April 15th. BTIG Research lowered St. Jude Medical from a “buy” rating to a “neutral” rating in a research report on Monday, April 18th. They noted that the move was a valuation call. Wedbush reaffirmed an “outperform” rating and set a $70.00 price target on shares of St. Jude Medical in a research report on Thursday, April 21st. Finally, Canaccord Genuity reaffirmed a “hold” rating on shares of St. Jude Medical in a research report on Wednesday, April 20th. Twenty-two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. St. Jude Medical has an average rating of “Hold” and a consensus price target of $75.93.

The firm has a market cap of $23.80 billion and a price-to-earnings ratio of 36.32. The company’s 50 day moving average price is $80.19 and its 200-day moving average price is $66.73.

St. Jude Medical (NYSE:STJ) last issued its quarterly earnings results on Wednesday, July 20th. The medical technology company reported $1.06 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.06. During the same period in the previous year, the company posted $1.07 earnings per share. The business had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.55 billion. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. Equities analysts predict that St. Jude Medical Inc. will post $4.06 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 30th will be issued a dividend of $0.31 per share. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date is Wednesday, September 28th.

Several large investors recently made changes to their positions in the stock. Marshall Wace LLP raised its stake in shares of St. Jude Medical by 396.9% in the fourth quarter. Marshall Wace LLP now owns 286,788 shares of the medical technology company’s stock worth $17,715,000 after buying an additional 229,078 shares during the period. Dimensional Fund Advisors LP raised its stake in St. Jude Medical by 32.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 823,890 shares of the medical technology company’s stock valued at $50,894,000 after buying an additional 199,858 shares during the last quarter. I.G. Investment Management LTD. raised its stake in St. Jude Medical by 29.7% in the fourth quarter. I.G. Investment Management LTD. now owns 228,600 shares of the medical technology company’s stock valued at $14,121,000 after buying an additional 52,300 shares during the last quarter. Principal Financial Group Inc. raised its stake in St. Jude Medical by 4.3% in the fourth quarter. Principal Financial Group Inc. now owns 432,163 shares of the medical technology company’s stock valued at $26,694,000 after buying an additional 17,640 shares during the last quarter. Finally, Suntrust Banks Inc. raised its stake in St. Jude Medical by 60.7% in the fourth quarter. Suntrust Banks Inc. now owns 41,483 shares of the medical technology company’s stock valued at $2,561,000 after buying an additional 15,672 shares during the last quarter.

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.